$PPBT News
Last published 1w ago
- 1w agoPPBTPurple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR SymposiumGlobeNewswireOral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology
- 2mo agoPPBTNew U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific AntibodiesGlobeNewswireREHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy
- 3mo agoPPBTPurple Biotech Reports Second Quarter 2026 Financial ResultsGlobeNewswireNew preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240's anti-tumor activity, favorable safety and
- 5mo agoPPBTPurple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic WindowGlobeNewswireNon-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared
- 6mo agoPPBTPurple Biotech Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswireNew data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples Established CAPTN-3 Scientific Advisory Board
- 6mo agoPPBTPurple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240GlobeNewswireData, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment
- 6mo agoPPBTPurple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody PlatformGlobeNewswireScientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3's advancement toward clinical-stage immunotherapy development SAB leverages expertise in
- 7mo agoPPBTPurple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody PlatformGlobeNewswireCollaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery
- 8mo agoPPBTPurple Biotech Announces CEO TransitionGlobeNewswireGil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a
- 8mo agoPPBTPurple Biotech Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireFocus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting
- 8mo agoPPBTPurple Biotech Announces Plan to Implement ADS Ratio ChangeGlobeNewswireADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a
- 10mo agoPPBTPurple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240GlobeNewswireIM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating
- 11mo agoPPBTPurple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025GlobeNewswireData demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic
- 11mo agoPPBTPurple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual CongressGlobeNewswireNew data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech
- 12mo agoPPBTPurple Biotech Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInitiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of
- 1y agoPPBTPurple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 PlatformGlobeNewswireAchieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific
- 1y agoPPBTPurple Biotech Announces Receipt of Nasdaq Minimum Bid Price NotificationGlobeNewswireREHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor
- 1y agoPPBTPurple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor ResistanceGlobeNewswireA Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple
- 1y agoPPBTPurple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsGlobeNewswireREHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor
- 1y agoPPBTPurple Biotech Announces Pricing of Up To $18 Million Public OfferingGlobeNewswire$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.
- 1y agoPPBTPurple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount SinaiGlobeNewswireMt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and the
- 1y agoPPBTPurple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2GlobeNewswireEncouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward
- 1y agoPPBTPurple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireREHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor
- 1y agoPPBTPurple Biotech Reports Second Quarter 2025 Financial ResultsGlobeNewswirePlatform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3
- 1y agoPPBTPurple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025GlobeNewswireREHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to
- 1y agoPPBTPurple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck CancerGlobeNewswirePhase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance
- 1y agoPPBTPurple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody PlatformGlobeNewswireREHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to
- 1y agoPPBTPurple Biotech Reports First Quarter 2025 Financial ResultsGlobeNewswireFinal CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting
- 1y agoGMDALPTXPPBTWSTPurple Biotech Appoints Shai Lankry as Chief Financial OfficerGlobeNewswireU.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a
- 1y agoPPBTPurple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched SubgroupsGlobeNewswireStatistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor
- 1y agoPPBTPurple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck CancersGlobeNewswireActivated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancerNT219's mechanism of action informs how it can restore
- 1y agoPPBTPurple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal CancerGlobeNewswireFindings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of brain metastasis in
- 1y agoPPBTPurple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025GlobeNewswireREHOVOT, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek
- 1y agoPPBTPurple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research MeetingGlobeNewswireREHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek
- 1y agoPPBTPurple Biotech Reports Fourth Quarter and Full-Year 2024 Financial ResultsGlobeNewswireCompleted successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with planned
- 1y agoPPBTPurple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major MarketsGlobeNewswireNT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple
- 1y agoPPBTPurple Biotech Advances NT219 into Phase 2 Head and Neck Cancer TrialGlobeNewswireNT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux) The
- 1y agoPPBTPurple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody PlatformGlobeNewswireCollaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types.CAPTN-3 antibodies are
- 1y agoPPBTPurple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewswireREHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune
- 1y agoPPBTPurple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewswireREHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune
- 1y agoPPBTPurple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic CancerGlobeNewswireFinal data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints A biomarker enriched patient population analysis based on
- 1y agoPPBTPurple Biotech Reports Third Quarter 2024 Financial ResultsGlobeNewswireTopline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated
- 2y agoPPBTPurple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathGlobeNewswirePatients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for
- 2y agoPPBTPurple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewswireCAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer
- 2y agoPPBTPurple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewswireCAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer REHOVOT, Israel, Oct.
- 2y agoPPBTPurple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24GlobeNewswireHigh CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1
- 2y agoPPBTPurple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer ResearchGlobeNewswireREHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that
- 2y agoPPBTPurple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireREHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that
- 2y agoPPBTPurple Biotech Reports Second Quarter 2024 Financial Results and Business HighlightsGlobeNewswirePositive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free
- 2y agoPPBTPurple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price RuleGlobeNewswireREHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies